Session Poster

• 1 • Biomarkers of mesothelial cell EMT, carcinogenesis and mesothelioma invasiveness in experimental rat models > D. Daniel POULIQUEN • 10 • The role of hyperthermia in intraperitoneal chemotherapy on abdominal tissue concentrations of cisplatin – insights from a porcine model > C. Christina HARLEV • 100 • Neo-adjuvant intraperitoneal chemotherapy combined with systemic therapy prior to CRS and HIPEC for patients with resectable colorectal peritoneal metastases: Protocol of the multicenter, phase II, INTERACT-PLUS trial > J. Julie HAMM • 101 • Peritoneal carcinomatosis – or just gallstones? > N. Nicholette GOH • 102 • A new proteomic approach to detect and characterise microorganisms in Peritoneal Mucinous Carcinomatosis > A. Antonio ROMERO-RUIZ • 103 • Intraperitoneal chemotherapy combined with Cell-free and concentrated Ascites Reinfusion Therapy (CART) for patients with massive malignant ascites due to peritoneal metastasis of gastric cancer > R. Rihito KANAMARU • 104 • Influence of splenectomy in patients with peritoneal metastases following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on postoperative complications, recurrence and survival. > L. Lana GHANIPOUR • 105 • Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Colon Cancer Patients at High Risk of Peritoneal Metastases: An Individual Patient Data Meta-Analysis > J. Julie HAMM • 106 • Phase 1 study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) with Paclitaxel for Peritoneal Carcinomatosis – PIPAC2 Study > R. Robert John WALSH • 107 • Comprehensive picture of colorectal peritoneal metastasis- a single center experience > V. Valérie KESSELER • 108 • A single cell atlas of colorectal peritoneal metastases > J. Jesse DEMUYTERE • 109 • Multimodal Therapy with Aggressive Cytoreductive Surgery for Recurrent Uterine Leiomyosarcoma Improves Survival > B. Byrne LEE • 110 • Phase I Trial of Intra-tumoral Lipopolysaccharide Injection in Peritoneal Tumors > P. Patrick WAGNER • 111 • Intra-cavitary Tocilizumab Immunotherapy for Malignant Pleural Effusions and Ascites: Phase I Protocol Rationale and Preliminary Results > P. Patrick WAGNER • 113 • Pushing the Limits of Oncological Treatment in Elderly Patients: Results of an Aggressive Policy for Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and HIPEC > D. Daniel BENCHIMOL • 114 • Intraperitoneal Paclitaxel Chemotherapy Induces Eosinophil Recruitment to the Peritoneal Cavity: Implications for Tumor Response in Gastric Cancer Peritoneal Metastasis > M. Misaki MATSUMIYA • 115 • The outcome of patients scheduled for CRS and HIPEC while only undergoing explorative laparotomy > I. Ingvar SYK • 116 • Factors influencing survival for patients with initially unresectable peritoneal surface malignancies (PSM) treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) : analysis of a large prospective cohort > R. Ran ORGAD • 117 • Advantages and Limitations of Minimally Invasive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei of Appendiceal Origin > T. Thikhamporn TAWANTANAKORN • 118 • Confirmation of Radiological Peritoneal Carcinomatosis Index Score with Diagnostic Laparoscopy in Gastric Peritoneal Carcinomatosis > Ö. Özgül DÜZGÜN • 119 • Urological Organ Resections in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy > Ö. Özgül DÜZGÜN • 12 • Immediate second look after cytoreduction of colorectal or ovarian carcinomatosis. Invisible Gorilla effect? > L. Lola COSSE • 120 • Peritoneal Carcinomatosis in the Elderly: Too Old for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)? > S. Sina YADEGARYNIA • 121 • The outcome of ERAS Pathways Implementation with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with Peritoneal Metastasis. Multi Centres Experience > W. Wael ABDEL GAWAD • 122 • Surgical treatment of Rectal Peritoneal Metastases in a primary tumor treated with neoadjuvant chemoradiotherapy: A Systematic Review. > L. Leonardo LINO-SILVA • 123 • Complex Management of Umbilical Hernia Revealing Pseudomyxoma Peritoneal from Low-Grade Appendiceal Mucinous Neoplasm: A Case Study > L. Leonardo LINO-SILVA • 124 • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and liver resection is a treatment option for patients with peritoneal and liver metastases from colorectal cancer > V. Vegar Johansen DAGENBORG • 125 • CRS-HIPEC in potentially curative treatment of primary advanced high grade serous ovarian-, tubal- and peritoneal cancer (OC). A pilot phase 2 study. > A. Anne DØRUM • 126 • Ex vivo imaging unravels the potential clinical utility of Cyph-11 in the detection of peritoneal metastases > X. Xing Yi, Sarah ONG • 127 • Intestinal obstruction-free survival as an end-point for peritoneal surface disease studies > J. Jan FRANKO • 128 • Quality of life and cost analysis of patients with unresectable peritoneal metastases after pressurized intra-peritoneal aerosol chemotherapy (PIPAC) > B. Benjamin PAIK • 129 • Preliminary Pharmacokinetic Results of a Phase I Dose-finding Study with Intraperitoneal Aerosolized Nanoliposomal Irinotecan in Patients with Peritoneal Metastases. > J. Judith VAN OVOST • 13 • Compliance and toxicity of intraperitoneal chemotherapy in metastatic colorectal and appendiceal cancer: Results of the randomized multicenter Intraperitoneal Chemotherapy After cytoReductive Surgery (ICARuS) trial > G. Georgios KARAGKOUNIS • 130 • Intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis: Experience of 100 cases in a general hospital in Japan.. > T. Tamaki KONISHI • 131 • Single-cell RNA sequencing reveals unprecedented insights into the tumor immune microenvironment of colorectal cancer peritoneal metastases > S. Sam ERNST • 132 • Diagnostic Performance of DW-MRI in Advanced Ovarian Cancer: First Results of the Dutch Prospective Multicenter Mission Trial > M. Max LAHAYE • 133 • Advancing Intraperitoneal Drug Delivery: NIR-Mediated Specificity Enhancement for Studying Electric Field-Driven Nanoparticle Penetration > N. Nidda SAEED • 134 • Preliminary data from randomized multicenter phase III trial PIPAC VEROne > F. Francesco CASELLA • 135 • Realistic gap between surgical and pathological staging of PCI in cytoreductive surgery (CRS) for appendiceal and colo-rectal mucinous neoplasms: Ten-years single center experience > F. Francesca MELONI • 136 • High dose iron infusion (ferric isomaltose/ derisomaltose) before CRS-HIPEC procedure: improvement in patients outcomes after surgery > T. Tarcisio REIS • 137 • Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) Leads to Sustained Long-term Quality of Life in Patients with Peritoneal Surface Malignancies > M. Mariaugusta MONTEALEGRE • 138 • The prognostic role of KRAS and GNAS in the prediction of survival outcomes in PMP > G. Gaia COLLETTI • 139 • Outcome of patients with a peritoneal surface malignancy referred to a tertiary center specialized in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy > L. Lizzel VAN DER SNEE • 14 • The use of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in pediatric peritoneal metastasis > J. John SPILIOTIS • 140 • Building a Peritoneal Surface Malignancy Unit: diagnosis, treatment and palliation of peritoneal carcinomatosis > S. Silvia GUERRERO-MACÍAS • 141 • CRS-HIPEC following Neo-adjuvant Bidirectional Pressurized Intraperitoneal aerosol chemotheraphy (PIPAC) with systemic chemotheraphy In Primarily Advanced inoperable epithelial ovarian cancer > C. C. ROHIT KUMAR • 142 • Optimizing the pathological diagnosis of diffuse malignant mesothelioma > F. Francesca Laura NAVA • 143 • Peritoneal pathologic response in patients with gastric cancer and carcinomatosis managed with chemotherapy with curative intent > S. Silvia GUERRERO-MACÍAS • 145 • Evaluating the Impact of Indocyanine Green on assessing bowel perfusion in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy > C. C. ROHIT KUMAR • 146 • Improving overall survival for patients with CRC-PM with dedicated care pathways; result of CRS-HIPEC, a Northwestern Netherlands, two center cohort > L. Lars VAN KESTEREN • 147 • A single, tertiary cancer care centre experience of management of Colorectal Peritoneal Metastasis > S. Satya Niharika VADISETTI • 149 • Utility of Left Lateral Liver Lobectomy in Removing Retrohepatic Lesions during Cytoreductive Surgery for Low-grade Mucinous Carcinomatosis > V. Vadim GUSHCHIN • 15 • A phase II study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. > N. Naminatsu TAKAHARA • 150 • Epithelioid malignant mesothelioma discovered following peritonitis: About a case > R. Rania OSMAN • 151 • A single-center retrospective study of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancies > K. Konstantinos ILIAKOPOULOS • 152 • Opportunistic Cholecystectomy during cytoreductive surgery for secondary peritoneal malignancies > S. Silvia GUERRERO-MACÍAS • 153 • Appendiceal adenocarcinoma discovered during acute perforated appendicitis: a potential contribution of prophylactic CRS and HIPEC, a French BIGRENAPE group study > E. Elsa LEIRITZ • 154 • Complications and mortality rate of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam results analysis > R. Rea LO DICO • 155 • CRS-HIPEC in Colorectal Cancer: Experience from a Tertiary Cancer Care Centre in India > A. Ankit SHARMA • 156 • HSF-1/miR-145-5p transcriptional axis enhances hyperthermia intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis > R. Rea LO DICO • 157 • Differential tumor microenvironment (TME) changes in ovarian cancer (OC) responder versus non-responder to pressurized intraperitoneal aerosolized chemotherapy (PIPAC) – a single cell transcriptomics analysis > T. Thanh DELLINGER • 16 • Palliative Care Education for Surgical Oncologists: A Systematic Review of Current Curriculum and Educational Outcomes > S. Sabrina Hui Xian CHEOK • 160 • It's not just what you've got, it's where you've got it: comparison of perioperative and oncological outcomes in CRS/HIPEC for Rectal vs. Colon cancer > D. Daniele MOREZZI • 161 • The Impact of Multidisciplinary Team Discussion on Surgical Decision Making in Patients with Peritoneal Surface Malignancies: Model for Multi-Institutional International Cooperation > W. Wael ABDEL GAWAD • 162 • Reviving HIPEC: enhancing survival rates with curative intent hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. > D. Dani CASTILLO • 163 • Effects of center’s experience on outcomes of Cytoreductive surgery and HIPEC in rare peritoneal diseases > S. Shigeki KUSAMURA • 164 • What is the proposed strategy offer by the different RENAPE unit after complete LAMN (Low grade mucinous appendicular tumors) resection in a primary care center : need for a new consensus ? > M. Marc POCARD • 165 • Engineering and preclinical validation of an impaction-based PIPAC nebuliser (Capnotip®) with a spraying angle over 150° and improved aerosol homogeneity > I. Iaroslav SAUTKIN • 166 • A supramolecular injectable pH-responsive hydrogel tailor-made to improve intraperitoneal therapy: Results from preclinical evaluation in minipigs and rodent models for peritoneal metastases of colorectal and ovarian origin. > G. Geert VAN ALMEN • 167 • It is what the surgeon does not see that kills the patient > P. Paul SUGARBAKER • 168 • Initial Experience Mini-Invasive Robotic Cytoreduction and HIPEC for Peritoneal Carcinomatosis: A Promising Approach > A. Andrea BERTOLUCCI • 169 • Intraperitoneal paclitaxel treatment combined with S-1+ Oxaliplatin for gastric cancer with peritoneal metastasis followed by conversion surgery > S. Shin SAITO • 17 • FDG-PET/CT as a method of patient selection and response evaluation in patients with peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy. The PIPAC-OPC7 study > M. Martin GRAVERSEN • 170 • Early outcomes of a new colorectal peritoneal metastases service for Wales > J. Jody PARKER • 171 • Pilot study on electronic patient reported experience and positive psychiatry outcome measures during PIPAC directed therapy > S. Sofie HALD NIELSEN • 172 • The Microbiome of Pseudomyxoma Peritonei: A Scoping Review > H. Helen MOHAN • 173 • Assessment of Role of Enhanced Recovery After Surgery (ERAS) Protocols in Patients undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Prospective Feasibility Study > P. Prosenjit DAS • 175 • Clinical pathway and technique of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed therapy > P. Pernille Schjødt HANSEN • 176 • Safety and effect of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed therapy against malignant pleural effusion and pleural metastasis > P. Pernille Schjødt HANSEN • 177 • Implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) for patients with malignant pleural effusion - Protocol for the Danish phase I PITAC-OPC5 trial > P. Pernille Schjødt HANSEN • 178 • Systematic review of endpoints in clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy > B. Ben Yaacov ALMOG • 179 • Molecular profiling of peritoneal metastatic gastric cancer > J. Jieun LEE • 18 • Prehabilitation in Peritoneal Surface Malignancy Patients undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy: A Qualitative Research Study > H. Hann Natalie SOH • 180 • Enhanced Recovery After Surgery (ERAS) Implementation in Cytoreductive Surgery (CRS) and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC): Insights from Italian Peritoneal Surface Malignancies Expert Centers > M. Manuela ROBELLA • 181 • Peritoneal Mesothelioma Patient Experience with long term survival (10+ years) after CRS, HIPEC and adjuvant Chemotherapy > S. Sara BABIN • 182 • Acute immune activation, anti-tumor activity and survival benefit of intraperitoneal chimeric oncolytic virus, CF33-hNIS alone and combined with systemic anti-PD-L1 treatment in an immunocompetent mouse model of gastric cancer peritoneal metastasis > A. Annie YANG • 184 • Utility of peritoneal lavage fluid for RNA profiling of peritoneal metastasis > S. Sönke DETLEFSEN • 185 • First report of success for delivering Mitomycin C with a thermogel in a big animal model with positive pharmacology and surgical security > C. Christian MOUAWAD • 186 • Influence of lung metastasis on outcomes of curative management of peritoneal metastasis from colorectal cancer > A. Ajinkya PAWAR • 187 • Elevation of tumour markers is a risk factor for decreased survival and recurrence in patients with colorectal peritoneal metastastes treated by cytoreductive surgery and HIPEC > N. Niccolo ALLIEVI • 188 • HIPEC for gastric cancer: A multicenter retrospective Canadian study > F. Florence BÉNARD • 19 • Occupational safety and therapeutic effect of paclitaxel according to types of formulation aerosolized during rotational intraperitoneal pressurized aerosol chemotherapy for peritoneal metastasis > H. Hee Seung KIM • 190 • Real-World Application of Cytalux to Illuminate Hidden Peritoneal Disease in Ovarian Cancer Surgery > E. Ekaterina BARON • 191 • Impact of body mass index on surgical and oncological outcome after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) > A. Anne Cécile EZANNO • 193 • Establishing an Onsite Surgical Training Centre at a Major Teaching University Hospital & National Peritoneal Malignancy Institute in Dublin, Ireland > M. Mohammad Faraz KHAN • 194 • Immune checkpoint inhibitors for patients with peritoneal metastases of dMMR colorectal cancer. > A. Arend AALBERS • 195 • Postoperative leukopenia after CRS and HIPEC for carcinomatosis of colorectal adenocarcinoma – causes and implication on outcomes. A Swedish population-based study. > M. Mattias LEPSENYI • 196 • Retroperitoneal lymph node dissection – How I Do It > G. Gurpreet SINGH • 197 • Experience of Cytoreductive surgery and HIPEC - A Multicentre retrospective study > O. Ola AL HAMDANI • 198 • Is systemic therapy harmful in certain cases of metastatic appendiceal adenocarcinoma?: The compelling need to incorporate tumor differentiation in determining the use of systemic therapy > S. Steve KWON • 199 • First-in-kind biologics targeting PAI-1 in Peritoneal Metastases Identified from Large Scale Proteomic Analysis of Ascites Integrated with a Drug Discovery Phage Display Approach > C. Chin Ann Johnny ONG • 2 • Clinical evaluation of Icodextrin delivery as pressurized aerosol (PIPAC): Pilot study of antiadhesive - peritoneal effects > X. Xavier DELGADILLO • 20 • Theoretical basis of comprehensive treatment for patients with peritoneal metastasis > Y. Yutaka YONEMURA • 200 • Potential role of Intraoperative Peritoneal Cytology in decission-making for the indication of HIPEC administration > S. Santiago GONZÁLEZ-MORENO • 201 • The Interplay of Complete Cytoreduction, HIPEC and Fibrosis in High-Grade Goblet Cell Adenocarcinomas of the Appendix with Peritoneal Carcinomatosis > P. Panagiota Chrysovalanto KOUKOUTSIDI • 202 • Polymer Brush-Grafted Single-Atom Nanozyme with High Catalytic Activity, Tumor Targeting Ability, and Biocompatibility for Colorectal Peritoneal Metastasis Treatment > X. Xiusen QIN • 203 • Synchronous peritoneal metastases from esophageal cancer in a nationwide cohort: an overview of the incidence, risk factors, treatment and survival. > R. Ravi SEUTER • 204 • Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients - the PIPAC-OPC3 trial > M. Martin GRAVERSEN • 205 • Preliminary study on feasibility of intraperitoneal continuous aerosolized fluids delivery to perform CIPAC (Continuous IntraPeritoneal Aerosolized Chemotherapy). > M. Marco VAIRA • 206 • Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) using Open and Closed abdomen techniques for Colorectal Peritoneal Metastases and Peritoneal Pseudomyxoma Recurrences: results from six French expert centers > A. Anne Cécile EZANNO • 207 • Perioperative systemic therapy for resectable colorectal peritoneal metastases: A critical systematic review. > T. Teun VAN DEN HEUVEL • 208 • The role of primary tumor resection in stage IV gastric cancer patients > M. Marion WELTEN • 209 • Risk Factors and Outcomes for Postoperative Evisceration within 30 Days of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) using open and closed abdominal techniques for Peritoneal Carcinomatosis. > C. Catherine ARVIEUX • 21 • Feasibility and Efficacy of An Integrated Tertiary-Primary Care Team in Peritoneal Surface Malignancy Patients Following Major Abdominal Surgery > S. Schin BEK • 210 • Overall survival in colorectal peritoneal metastases after a discontinued CRS-HIPEC procedure: added value of palliative treatment. > T. Teun VAN DEN HEUVEL • 211 • Influence of biennial fecal immunochemical testing (FIT) for colorectal carcinoma on the incidence of synchronous colorectal peritoneal metastases > L. Laskarina GALANOS • 212 • Evaluation of predictive factors of delayed return to intended oncology treatment after interval cytoreductive surgery in advanced epithelial ovarian cancer > G. Gatien POUTREL • 213 • Patient-derived Decellularized Extracellular Matrix Scaffolds to Develop an ex vivo Model of Pseudomyxoma Peritonei in a More Relevant Biological Context > L. Luca VARINELLI • 214 • Long-Term Survival in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Treatment Centers > X. Xin Li LIANG • 215 • Prophylactic HIPEC in colon cancer patients with minimal serosal involvement: A pilot study > I. Ihab Saad Hussein HUSSEIN AHMED • 216 • Prognostic value of DNA ploidy, stroma, and nucleotyping in colorectal synchronous peritoneal metastasis > X. Xiusen QIN • 217 • The landscape of practice and training in the peritoneal surface malignancy field > C. Claramae CHIA SHULYN • 218 • Impact of HIPEC Introduction in interval debulking surgery for advanced ovarian cancer: A real-world population study > B. Blanca VALENZUELA MENDEZ • 219 • Treatment of disseminated Appendiceal Goblet cell adenocarcinoma with Cytoreductive surgery and HIPEC. > J. Jovica VASILJEVIC • 22 • Does the HyaRegen® gel used after PIPAC procedures have an effect on the progression of colorectal peritoneal metastases? > M. Marie Laure PERRIN • 220 • Study of the immune microenvironment in peritoneal metastases from colorectal cancer > T. Thomas BARON • 221 • Monocentric experience of interventional radiology approach in treatment of postoperative complications after complete cytoreductive surgery +/- HIPEC > I. Isabelle SOURROUILLE • 222 • Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: the interim analisys of Nab-PIPAC trial > A. Andrea DI GIORGIO • 223 • Cytoreductive surgery with HIPEC in colorectal cancer - results from an initial experience at a major cancer center in India > B. Bhawani PATHAK • 224 • Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Outcomes from a Tertiary Cancer Care Center in Northern India > B. Bhawani PATHAK • 225 • Prognostic factors for survival in ovarian cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: 11-year retrospective review > A. André VALE GUIMARÃES • 226 • Prospective assessment of the role of preoperative modified Glasgow Prognostic Score in predicting Short-Term Quality of Life in patients with peritoneal surface malignancies undergoing cytoreductive surgery > P. Prosenjit DAS • 227 • The evolution of treatment in Peritoneal Surface Malignances: 700 patients treated in a single high-volume center. > A. Andrea DI GIORGIO • 228 • Role of RPLND in Carcinoma Ovary Analysis from Tertiary Care Centre in India > B. Bittu BHUKKAL • 229 • Impact of the SCODA Program (Surgical Complication Optimization through Diet and Activity) on Outcomes in Cytoreductive Surgery with or without HIPEC > A. Amine SOUADKA • 23 • Is pressurized intraperitoneal aerosol chemotherapy (PIPAC) feasible in a rabbit model of gastric peritoneal metastases? > S. Sylvia BARDET-COSTE • 230 • Overcoming Resource Constraints: Implementing a Peritoneal Surface Malignancy Program in an LMIC Setting > A. Amine SOUADKA • 231 • Two-stage surgery in pseudomyxoma peritonea > M. Marina JIMÉNEZ MONASTERIO • 232 • Evaluating Peritoneal Surface Malignancy Management in North Africa: Outcomes from a Multi-Center Retrospective Audit > A. Amine SOUADKA • 233 • Seminal vesicles involvement is an unfavorable site of colorectal peritoneal metastases. A 10 year experience seminal vesicle resection as part of CRS and HIPEC > O. Omar ALBAQMI • 234 • The influence of screening on colorectal peritoneal metastases in the Netherlands: The effect on incidence, treatment and survival, a synopsis of two Dutch cohort studies > L. Laskarina GALANOS • 235 • US Multicenter Dose-escalation Phase 1 trial of Mitomycin C Pressurized Intraperitoneal Aerosolized Chemotherapy in Combination with Systemic Chemotherapy for Appendiceal and Colorectal Carcinomatosis: Interim Results > M. Mustafa RAOOF • 236 • Clinopathological outcomes of immunotherapy for malignant peritoneal mesothelioma patients--a 4-year review of national multidisciplinary team video-conference meeting > S. Siu Yan KOK • 237 • Genetic Mutations in Colorectal Cancer Cases with Peritoneal Metastases and Liver Involvement with High Pre-cytoreductive CEA Value > D. David MORRIS • 238 • Rationale and Study Design of the KOV-HIPEC-02R: A Randomized, Multicenter, Open-label Phase III trial of Hyperthermic Intraperitoneal Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer > K. Kim JIN HEE • 239 • Clinical Value of Different Strategies of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei of Appendiceal Origin: A Retrospective Clinical Study > Y. Yan LI • 240 • Phase I PIANO Trial - PIPAC-Oxaliplatin and Systemic Nivolumab Combination for Gastric Cancer Peritoneal Metastases: Clinical and Translational Outcomes > H. Hon Lyn TAN • 241 • Cutaneous panniculitis post hyperthermic intraperitoneal chemotherapy with mitomycin C (MMC-HIPEC), a rare and unrecognized side effect > E. Emmanuel RIBEREAU • 242 • Safety and Efficacy of Total Parental Nutrition in Patients with Peritoneal Surface Malignancies undergoing Palliative Gastro-intestinal Surgery > M. Moses V TAN • 243 • DEFYING LIMITS: A Case Report on the Experience of a Low Resource Hospital in the Philippines on its First Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy > L. Louie Czelline DE LEON • 244 • The EPICH Trial: a multicenter pre-post study to implement ERAS Program for patients with peritoneal surface malignancies treated by Citoreductive Surgery and HIPEC > M. Manuela ROBELLA • 245 • A systematic review and meta-analyses on the efficacy of stenting for gastric outlet obstruction with peritoneal carcinomatosis > M. Muhammad Danish BIN MASSURYONO • 246 • Advancing Intraperitoneal Chemotherapy: Nano Aerosol Chemotherapy (NAC) As A Promising Solution Overcoming PIPAC Limitations > P. Pranjal BANTHIA • 247 • Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) For Unresectable Peritoneal Metastases In Ovarian Cancer: Insights From An Indian Tertiary Care Cancer Center'S Initial Experience > P. Pranjal BANTHIA • 248 • Should transmural recto-sigmoid invasion alone in ovarian cancer be considered as FIGO stage IV? -Opinion from tertiary cancer care centre in India > B. Bittu BHUKKAL • 249 • Rationale and Study Design of the KOV-HIPEC-04: A Phase III Randomized Controlled Trial in Primary Stage Three and Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS) > E. Eungyeong WOO • 25 • Two-Stage Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies > G. Gabriel Liberon JAZON • 250 • Failure to intended adjuvant treatment impair prognosis in patients with gastric peritoneal carcinomatosis treated with cytoreductive surgery and HIPEC > J. Jean PINSON • 251 • Outcomes of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients- Five years of experience > H. Haggai BENVENISTI • 252 • Outcomes of patients treated with hyperthermic intraperitoneal chemotherapy and cytoreductive surgery compared to surgery alone in epithelial ovarian cancer: a systematic review and met-analysis > D. David ATALLAH • 253 • PIPAC. Starting a Program in Chile. Indications and Results. > M. Mario URIBE • 254 • The Impact of KRAS Mutation Status on Postoperative Outcomes for Patients Undergoing Cytoreductive Surgery for Peritoneal Carcinomatosis of Appendiceal Origin > P. Peter BOROWSKY • 255 • The Impact of Peritoneal Carcinomatosis Index Reduction on Post-Operative Morbidity and Recovery in Patients with Peritoneal Surface Malignancy from Appendiceal Origin after CRS/HIPEC > P. Peter BOROWSKY • 256 • Outcomes of CRS/HIPEC fore peritoneal mesothelioma after conversion to surgery by bidirectional chmotherapy > I. Isabelle SOURROUILLE • 257 • Outcomes of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Unresectable Peritoneal Metastasis: Insights from a Single-Center Study > J. José Pedro VIEIRA DE SOUSA • 258 • Cytoreductive surgery and HIPEC have a positive impact on the overall survival of patients with BRAF V600E-mutated peritoneal metastatic colorectal cancer > S. Safak GÜL-KLEIN • 259 • Zero renal impairment post Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with Cisplatin > A. Abdullah ABDULRAHEM • 26 • Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Selected Patients of Colorectal Cancer with peritoneal and lung metastasis > A. Ajinkya PAWAR • 260 • Laparoscopic radical appendectomy for appendicular mucocele, a video presentation > A. Abdullah ABDULRAHEM • 261 • NIPS or neoadjuvant chemotherapy followed by CRS + HIPEC for patients with peritoneal carcinomatosis from gastric cancer > M. Maria Luz FERNANDEZ VAZQUEZ • 262 • laparoscopic peritonectomy and HIPEC for the treatment of peritoneal metastasis > M. Mahdi ALZAMANAN • 263 • Ovarian Involvement In Patients Undergoing Surgery For Peritoneal Metastases of Colorectal Cancer– A Peritoneal Oncology Referral Center Study > M. Marina BOSCH RAMIREZ • 264 • Impact of timing of cytoreductive surgery and HIPEC in prophylactic treatment for colorectal cancer at risk of peritoneal metastasis: report of a monocentric experience. > M. Monica TOMASSI • 265 • Higher doses of cisplatin and doxorubicin increase objective regression rates (PRGS 1) and improve survival after pressurized intraperitoneal aerosol chemotherapy (PIPAC) for gastric cancer (GC) with peritoneal carcinomatosis (PC). > V. Vladimir KHOMIAKOV • 266 • Initial experience with Robotic Assisted CRS-HIPEC > A. Awad ALYAMI • 267 • Recurrence Patterns after CRS/HIPEC in Malignant Peritoneal Mesothelioma and Management Strategies: a Single-Institution Experience > P. Panagiota Chrysovalanto KOUKOUTSIDI • 268 • pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the management of unresectable peritoneal metastasis , experiance from Saudi arabia > M. Mahdi ALZAMANAN • 27 • The Impact of Body Mass Index on Postoperative Outcomes in Older Adults after Major Surgery > J. Jun Kiat Thaddaeus TAN • 270 • Immediate peritoneal immediate chemotherapy (EPIC) : an obsolete technic ? Analysis of series of 300cases. > S. Salah BERKANE • 271 • Synergestic effect of Oxaliplatin, ATR inhibitor and anti-PD1 combination, leads to colon cancer carcinogenesis eradication though deregulation of neutrophil homeostasis and increased PD1+ CD8+ Tcells population in mice. > C. Céline GONGORA • 272 • Surgery for Colorectal Peritoneal Carcinomatosis in no-expert Centers is associated with Tumor Persistence or Early Recurrence in Most Cases: A Bicentric Study of 106 Patients > B. Barbara NOIRET • 28 • The Impact of Prehabilitation on Functional Capacity & Outcomes in Surgical Oncology Patients Undergoing Major Abdominal Surgery: A Meta-Analysis > C. Charles Rong Zhang YAU • 29 • Preclinical evaluation of operational stability and drug delivery in a new device for hyperthermic intraperitoneal chemotherapy with negative pressure infusion capability > S. Seungmee LEE • 3 • The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy combined with Curative Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients – EPICURE: A multicentre, randomized study. > A. Alan Patrick AINSWORTH • 30 • Preclinical evaluation of the pharmacokinetics, drug exposure and toxicity in rotational intraperitoneal pressurized aerosol chemotherapy using gemcitabine > M. Muftaydinova Shakhnoza KIYOMIDDINOVNA • 31 • Gastrointestinal Quality of Life after Cytoreductive Surgery and HIPEC – What is the real impact? > M. Maria João MADEIRA-CARDOSO • 32 • Preclinical evaluation of the pharmacokinetics, drug exposure and toxicity in rotational intraperitoneal pressurized aerosol chemotherapy using pemetrexed > M. Muftaydinova Shakhnoza KIYOMIDDINOVNA • 33 • Isolated Lymphatic Spread in Ovarian Cancer: A Single-Center Retrospective Study > E. Elise SCHÜTZ • 34 • The Impact of Neighborhood-Level Disadvantage on Treatments and Outcomes in Newly Diagnosed Appendix Cancer > V. Vadim GUSHCHIN • 35 • Cytoreductive Surgery and HIPEC for Patients with Pseudomyxoma Peritonei and Liver Hilum Involvement: A Single Institution Experience > B. Brian WILLIAMS • 36 • Deep epigastric lymph node involvement in patients with ovarian and colorectal peritoneal metastasis > G. Gabriel LIBERALE • 37 • An Integrated Prehabilitation and Serious Illness Care Program in Patients with Peritoneal Surface Malignancy: A Prospective Pilot Study > A. Ai Ting Irene NG • 38 • How HIPEC plays a role along with CRS in all settings of advanced Epithelial Ovarian Cancer: A pilot study on genetic point of view. > M. M D RAY • 39 • Patterns of preoperative tumour markers can predict resectability and prognosis of peritoneal metastases – a clustering analysis > M. Malin ENBLAD • 40 • The textbook outcome in ovarian cancer: an interesting tool for comparing results between Surgical Peritoneal Units > F. Francisco Javier LA CUEVA • 41 • Measurement of survival according to textbook outcome and PCI in patients with interval surgery for carcinomatosis of ovarian cancer > F. Francisco Javier LA CUEVA • 42 • Impact of laparoscopic ultrasound during PIPAC directed treatment of unresectable peritoneal metastasis > M. Magnus Skov JØRGENSEN • 43 • Survival of patients with peritoneal versus non-peritoneal metastatic colorectal cancer given first-line palliative systemic therapy: a nationwide registry-based cohort study. > T. Teun KERKHOFF • 44 • Survival outcomes of patients with synchronous colorectal peritoneal metastases treated with “standard” therapy in Japan > H. Hiroshi NAGATA • 45 • Assessment of the Efficacy of Chemotherapeutic Agents in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) > D. David MORRIS • 46 • BromAc (Bromelain plus N-acetylcysteine) enhances Doxorubicin entry in ovarian and pancreatic cancer cells. > D. David MORRIS • 47 • First-line palliative systemic therapy alternated with oxaliplatin-based Pressurized Intraperitoneal Aerosol Chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II). > V. Vincent VAN DE VLASAKKER • 48 • Elucidating molecular mechanisms of Peritoneal Carcinomatosis in Colorectal Cancer through multi-omic analysis: integration of clinical and genomic profiling for enhanced detection of minimal residual disease > V. Valentino MARTELLI • 49 • Deep learning algorythm for peritoneal carcinomatosis detection. Performance through analysis of laparoscopic video recording. > F. Frédéric DUMONT • 5 • Malignant ovarian goiter: a rare and particular tumor about a case, literature review and treatment methods > A. Amanoullah Yacine BOUAYED • 50 • Developing an AI tool for accurate radiological assessment of peritoneal metastases > L. Lotte EWALS • 51 • Prospective study of adjuvant oxaliplatin-based PIPAC with concurrent intravenous 5-fluorouracil and folinic acid after curative surgery for pT4a/b colon cancer (Clinicaltrials.gov NCT06091683) > D. Dario BARATTI • 52 • Peritoneal metastases from mucinous adenocarcinoma of appendiceal vs. colorectal origin. An Italian multicenter comparative study > D. Dario BARATTI • 53 • Insights into the Clinical Prognosis of High-Grade Appendiceal Mucinous Neoplasms: Lymph Node Metastasis and Peritoneal Risks of HAMN > P. Peggy DARTIGUES • 54 • Incidence of Pseudoprogression and Hyperprogression in Patients with Peritoneal Mesothelioma Treated with Ipilimumab and Nivolumab > O. Owen MITCHELL • 55 • Targeted Gene Therapy for Peritoneal Dissemination via MicroRNA Modulation: A Novel Approachch > Y. Yuki KAEKO • 57 • Early postoperative immediate chemotherapy (EPIC) prevents diffuse peritoneal carcinomatosis recurrence. > S. Salah BERKANE • 58 • Intraperitoneal chemotherapy improves 5-year survival for colon cancer > S. Salah BERKANE • 59 • Immune Profiles in Colorectal Cancer Peritoneal Metastases: Who could benefit from immunotherapy? > E. Elinor BEXE LINDSKOG • 6 • Inter-reader agreement in calculation of the CT-PCI using e-PROMISE to evaluate colorectal peritoneal carcinomatosis > L. Laurence VILCOT • 60 • Preoperative Diagnostic Laparoscopy For Patients with Peritoneal Metastases May Predict Completeness of Cytoreductive Surgery > B. Beatrice SUN • 61 • Expression profiling of 800 mRNAs in peritoneal metastasis from pancreatic cancer treated with systemic chemotherapy and PIPAC > S. Sönke DETLEFSEN • 62 • Patterns of aggravation in gastric cancer patients with peritoneal metastases who underwent paclitaxel based intraperitoneal therapy > Y. Yasushi TSUJI • 63 • Feasibility and Efficacy of a Palliative Education Program for Peritoneal Surgeons and Trainees > L. Louis Choon Kit WONG • 64 • Development and Implementation of a Novel Language Processing Solution to Measure Health-Related Quality of Life following Major Abdominal Surgery in Peritoneal Surface Malignancy > X. Xi Zhi LOW • 65 • Comparison of 30-day major complications defined by NCI-CTCAE versus Clavien-Dindo classifications in patients with colorectal peritoneal metastases undergoing cytoreduction > W. Walid EL HOUT • 66 • The Impact of Age on Information Sharing Preferences of Patients with Peritoneal Surface Malignancies > B. Beatrice SUN • 67 • Impact of Successful Implementation of an Enhanced Recovery After Surgery (ERAS) Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy > B. Byrne LEE • 68 • Role of CRS HIPEC in Carcinoma Ovary where we stand today- With our experience from a tertiary referral oncology centre, India > M. M D RAY • 69 • Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Ovarian Cancer: Morbidity and Outcomes in Hispanics Vs non-Hispanics > M. Mariaugusta MONTEALEGRE • 7 • A multi-nozzle nebuliser does not improve tissue drug delivery during PIPAC > I. Iaroslav SAUTKIN • 70 • Perioperative Bevacizumab in patients undergoing Cytoreductive Surgery and HIPEC for colorectal peritoneal metastases: results of a phase II trial (BEV-IP) > D. Daryl CHIA • 71 • Interest of extracellular vesicles associated with PIPAC in a murine model of peritoneal carcinomatosis of colonic origin > P. Paul ROZENBAUM • 73 • Peritoneal tumour DNA in peritoneal fluid: emerging tool for peritoneal metastases detection > A. Antoine MARIANI • 74 • Impact of resected peritoneal surface area and risk factors on acute kidney injury following CRS and cisplatin-based HIPEC. > P. Philipp SCHREDL • 75 • Data completeness within the International Society for the Study of Pleura and Peritoneum (ISSPP) PIPAC database > M. Magnus Skov JØRGENSEN • 76 • Employing Integrative Analysis to Identify Novel Targets in Ascitic Fluid of Peritoneal Metastasis: Building upon Paracrine Analysis Methodologies > A. Andre Jing Yuen ANG • 77 • Correlation of KELIM score with Pathological PCI and chemo response grade and its validation as a prognostic predictor of survival after interval cytoreduction in advanced high grade serous ovarian cancer. > S. Snita SINUKUMAR • 78 • The sustained-release, oxaliplatin-loaded, multi-vesicular liposomal depot for intraperitoneal chemotherapy in a syngeneic mouse model of colon cancer with peritoneal metastasis > E. Eun Jung PARK • 79 • Nephrotoxicity associated to cytoreductive surgery combined with cisplatin-based HIPEC for peritoneal malignant disease: systematic review and meta-analysissis > C. Cristián GRILLO MARÍN • 8 • PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): an open label, non-comparative phase 1/2 dose escalation and expansion trial. > F. Frédéric DUMONT • 80 • Feasibility and safety of neoadjuvant intravenous and intraperitoneal chemotherapy (NIPS) for colorectal peritoneal metastasis > Y. Yoshimasa GOHDA • 81 • Presurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Urachal Adenocarcinomas: A multimodal treatment. > J. Javier SANDOVAL • 82 • Robust Prognostic Signature in Colon Cancer by Studying Ectopically Expressed Genes using Machine Learning > A. Aurélien SPINELLI • 83 • CRS with HIPEC in Colorectal peritoneal metastasis: A Clinical retrospective observational study from a tertiary cancer care center > S. Shwetal SONVANE • 84 • Effectivity of systemic CHEmotherapy on MUcnious Colon CAncer. CHEMUCCA study. (Part I: high risk stage II and stage III) > I. Irène TRINIDAD • 85 • Quantitative Assessment of histological Regression in Peritoneal carcinomatosis (QARP) as a modified scoring system after pressurized intraperitoneal aerosol chemotherapy – a pilot study > J. Jan Philipp RAMSPOTT • 86 • Exposure assessment of oxaliplatin between systemic and intraperitoneal route including PIPAC and HPIPAC (hyperthermic PIPAC) using swine experimental model > H. Hyung Ho KIM • 87 • A multicenter phase I study of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin with systemic nab-paclitaxel in recurrent ovarian cancer patients - Trial in progress > T. Thanh DELLINGER • 88 • Oxaliplatin penetration of peritoneum comparing Intravenous administration and intraperitoneal spraying method via a PIPAC and HPIPAC(hyperthermic PIPAC) > H. Hyung Ho KIM • 89 • Oxaliplatin concentration in blood and tissues between systemic administration and intraperitoneal spraying methods including PIPAC and HPIPAC( hyperthermic PIPAC) > H. Hyung Ho KIM • 9 • Bromelain and N-acetylcysteine combined with hyperthermic chemotherapy in mesothelioma cell lines > M. Michelle DIETZ • 91 • Does Incisional hernia reducible in patients undergoing Cytoreductive Surgery and HIPEC: An observational clinical study from a tertiary oncology center, India > M. M D RAY • 92 • Comparing doublet vs conversion neoadjuvant therapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal peritoneal metastatic disease > P. Peter CASHIN • 93 • Risk of anastomotic leakage after cytoreductive surgery with multiple anastomoses and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases > J. Johan TRANBERG • 94 • Effects of electrostatic precipitation during intraperitoneal aerosolized drug delivery: results from a realistic in vitro model > M. Mohammad RAHIMI GORJI • 95 • Comparison of the therapeutic efficacy of PIPAC Oxaliplatin versus PIPAC Cisplatin-Doxorubicin: experimental study in rabbit model with gastric peritoneal metastases > A. Abdelkader TAIBI • 96 • Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma: rationale and design of the IMMUNOPEC trial > M. Mitchell EMMERS • 97 • Using machine learning to detect at-risk patients of pulmonary embolisms after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy > M. Miguel ALBERTO VILCHEZ • 98 • Collaborative Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) – Latin American (LATAM) Group: Initial experience & settings. > X. Xavier DELGADILLO • 99 • Phase angle in patients with peritoneal carcinomatosis undergoing cytoreductive surgery after a prehabilitation program. > F. Francisco Javier LA CUEVA